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Objective: To investigate the effect of Tinospora crispa (T. crispa) extract on matrix
metalloproteinase-13 (MMP-13) expression and cell migration.
Methods: The cytotoxicity of T. crispa extract was examined by 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide assay on head and neck squamous cell carcinoma
(HNSCC) cell lines. The effect on expression of MMP-13 was analysed by RT-PCR and
ELISA. The migration was assessed by wound healing assay.
Results: MMP-13 mRNA was highly expressed in the metastatic human HNSCC cell
lines, HN22 and HSC-3. T. crispa extract at a concentration of 100.0 mg/mL caused about
50% reduction of cell survival. T. crispa extract at a non-toxic concentration of 12.5, 25.0
and 50.0 mg/mL signiﬁcantly suppressed MMP-13 mRNA expression and secreted MMP-
13 in both HN22 and HSC-3. The expression of tissue inhibitors of metalloproteinase-2
(TIMP-2) by HSC-3 cells was attenuated by 25.0 and 50.0 mg/mL of T. crispa extract.
Addition of the extract to cells in a wound healing assay showed inhibition of cell
migration by HN22 cells.
Conclusions: These data suggest that T. crispa could be considered as a potential
therapeutic drug to prevent metastasis of HNSCC.1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is one of
the most common malignancies, resulting in morbidity and
mortality worldwide [1]. Local invasion, lymphatic
dissemination and subsequent distant metastasis contribute to
the poor prognosis and decrease in survival rate [2]. Tumor
metastasis is a complex and multistage process. Degradation
of the extracellular matrix, e.g., the basement membrane, byproteinases such as matrix metalloproteinases (MMPs) is a key
event of tumor invasion and metastasis.
MMPs are a family of zinc-dependent endopeptidases, which
contain more than 25 members. MMPs are grouped as colla-
genases, gelatinases, stromelysins and membrane-type MMPs
based on their structure and substrate speciﬁcity. MMP-13 or
collagenase 3 plays a key role in the modulation of extracellular
matrix degradation and cell–matrix interactions associated with
inﬂammatory processes and metastasis [3,4]. In addition to type I
collagen as its main substrate, MMP-13 can cleave collagen
types II, III, IV, IX, X and XIV, laminin and ﬁbronectin [5].
MMP expression and activity are regulated at different levels
such as at the transcriptional level, mRNA stabilization and at
the translational level. In addition, the activity of MMPs is
modulated by tissue inhibitors of metalloproteinases (TIMPs).
Thus far, there are four different TIMPs (TIMP-1, -2, -3, -4),
whereas TIMP-1 and TIMP-2 are commonly identiﬁed in
HNSCC [6].an open access article under the CC BY-NC-ND
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many types of human cancer cells including breast, larynx,
stomach and intestine [7,8]. MMP-13 is highly expressed in
HNSCC compared to normal skin or oral mucosa [9,10]. It is well
established that the level of MMP-13 expression is correlated
with the invasive and metastatic phenotype of the HNSCC [11].
Targeted inhibition of this enzyme in both hepatocellular
carcinoma and mouse models can decrease tumor invasion and
growth [8]. Moreover, treatment with recombinant MMP-13
protein promoted angiogenesis in vitro and in vivo, leading to
aggressive tumor progression and metastasis [12]. These data
encourage the choice of MMP-13 as a therapeutic target in
cancer treatment.
Phytochemicals, bio-active components from plants, are
recently used as an alternative treatment for cancer due to their
extensive availability, but more importantly, because of their
potential of anti-cancer activity with minimal adverse effects
compared with chemotherapy. Epidemiological studies revealed
that the daily consume of certain phytochemicals effectively
decline the incidence of several types of cancers [13,14]. Bishayee
et al. proposed the synergistic effects of phytochemicals in fruits
and vegetables on cancer prevention [15].
Tinospora crispa (T. crispa) or Guduchi, a plant from the
Menispermaceae family, is an indigenous climber plant widely
distributed in Southeast Asia, particularly in Vietnam, Malaysia,
Thailand, Indonesia and India [16,17]. This medicinal herb is
traditionally used for treatment of inﬂammation, diabetes,
contusion, septicemia, fever, scabies and other tropical ulcer-
related disorders [18,19]. T. crispa has a potential to be a
source of natural antioxidants and anti-cancer agents [20]. A
previous study showed that T. crispa exhibited anti-
proliferative and anti-angiogenesis effects and could induce
apoptosis in certain human cancer cell lines such as MCF-7
(breast carcinoma), HeLa (cervical carcinoma), Caov-3
(ovarian carcinoma) and HepG2 (hepatocellular carcinoma)
[20–22]. Methanol extract of T. crispa was found to have a more
potent anti-proliferative effect on MDA-MB-231 and MCF-7
human breast squamous cell carcinoma than extracts obtained
with water or chloroform [20].
Although many pharmacological activities of T. crispa have
been reported, the effect of T. crispa as an anti-cancer drug in
HNSCC is still unknown. The aim of this study is to investigate
the effect of T. crispa on MMP-13 expression and HNSCC cell
migration.
2. Materials and methods
2.1. Preparation of T. crispa extract
Whole plants of T. crispa (300 g) were blended in 95%
ethanol and macerated for 5 days. The mixture was ﬁltered and
evaporated under reduced pressure to yield 7.32 g crude
T. crispa extract. This extract was dissolved in dimethyl sulf-
oxide as a stock solution at 50 mg/mL.
2.2. Cell culture
Four human cell lines derived from HNSCCs were used.
HN8 and HN22, primary and metastatic type of laryngeal
carcinoma, were provided by Professor J. Silvio Gutkind(NIDCR, NIH, USA). HSC-7 and HSC-3, primary and meta-
static type of tongue carcinoma, were provided by Professor
Teruo Amagasa (Tokyo Medical and Dental University,
Japan). All experimental protocols were approved by the
Ethical Committee, Faculty of Dentistry, Chulalongkorn Uni-
versity, Thailand (No. 071/2013). Cells were cultured at 37 C
in dulbecco's modiﬁed Eagle medium (DMEM) supplemented
with 10% fetal calf serum, 2 mmol/L L-glutamine, 100 IU/mL
penicillin, 100 mg/mL streptomycin, and 5 mg/mL amphotericin
B (Gibco BRL, Carlsbad, CA, USA) in a humidiﬁed atmo-
sphere of 5% CO2.
2.3. 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay
The cell viability of HNSCC cells was determined by MTT
test (Sigma, St. Louis, MO, USA). Brieﬂy, the cells were serum-
starved for 6 h and incubated with various doses of T. crispa
extract in serum-free DMEM for 48 h. The culture medium was
then aspirated, and incubated in 0.5 mg/mL MTT solution for
15 min in a CO2 incubator. Formazan crystals were eluted in a
detergent solution containing 1:9 dimethyl sulfoxide and glycine
buffer (0.1 mol/L glycine/0.1 mol/L sodium chloride at pH 10).
Optical density of solubilized solution was measured at 570 nm
in a microplate reader (Elx800; Biotek, Winooski, VT, USA).
The viable cell number of experimental groups was calculated as
relative to control group.
2.4. RNA extraction and RT-PCR
The total cellular RNA was extracted with Trizol reagent
(Molecular Research Center, Cincinnati, OH, USA). One
microgram of RNA sample was converted to cDNA by using
reverse transcriptase (ImpromII, promega, UK). Taq polymer-
ase (Invitrogen, Brazil) was used for PCR to detect MMP-13,
TIMP-1, TIMP-2 with glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) serving as a reference gene. Primers were
designed by published sequences from GenBank. The ampli-
ﬁcation proﬁle for MMP-13, TIMP-1 and TIMP-2 was dena-
tured for 1 min at 94 C, annealed for 1 min at 60 C, and
extented for 1.3 min at 72 C (30 cycles). The same proﬁle
with 22 cycles was used for GAPDH. PCR product was then
subjected to electrophoresis on 2% agarose gel and the band
intensity was measured by BIO-1D software (Scion, Frederick,
MA, USA).
2.5. ELISA
Measurement of secreted MMP-13 in the conditioned me-
dium was performed by using anti-human pro-MMP-13 ELISA
kits (R&D Systems, Minneapolis, MN, USA) followed the
manufacturer's protocol. The optical absorbance was measured
at 450 nm in a microplate reader.
2.6. Wound-healing migration assay
A wound healing assay was performed as described previ-
ously [23]. Brieﬂy, HN22 cells were seeded on 6-well plates and
incubated overnight yielding a conﬂuent monolayer. A “wound”
was made by dragging a sterile blue pipette tip along the center
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cells were incubated with 50.0 mg/mL T. crispa extract in serum-
free DMEM. Images of cell monolayer were captured at 0 and
24 h time points under the phase-contrast microscope with a
digital camera. The distance between the margins of the wound
in randomly selected ﬁelds was measured for the wound wide-
ness. Calculating method was:
Relative migration ratio = (distance at 0 h−distance at 24 h)/
distance at 0 h.
2.7. Statistical analysis
The data were reported as mean ± SD relative to the control
from three independent experiments. Statistical differences were
assessed by using student's t-tests for two-group comparisons or
One-way ANOVA followed by Dunnett's test for three or more
groups. A signiﬁcance level of 0.05 was considered in all sta-
tistical comparisons.
3. Results
3.1. MMP-13 expression in HNSCC cell lines
Figure 1 demonstrates the endogenous MMP-13 mRNA
expression in metastatic HNSCC cell lines compared with that in
primary HNSCC cell lines. A striking lower MMP-13 expres-
sion was observed in both HN8 and HSC-7. The quantitate data
showed that MMP-13 expression of HN22 was 2.5 fold of HN8
and HSC-3 was 5 fold of HSC-7.
3.2. Cytotoxic effect of T. crispa extract on HNSCC cell
lines
To evaluate possible cytotoxic effects of the T. crispa
extract, HN22 and HSC-3 were treated with a concentration of
12.5, 25.0, 50.0 and 100.0 mg/mL or dimethyl sulfoxideFigure 1. MMP-13 gene expression in metastatic HNSCC compared with
that in primary HNSCC.
A: The level of MMP-13 mRNA expression in HN8, HN22, HSC-7 and
HSC-3 analyzed by RT-PCR; B: Quantitation of MMP-13 expression in
HN22 and HSC-3 was normalized to GAPDH and represents as the
mean ± SD relative to HN8 and HSC-7, respectively; *: P < 0.05.(control) for 48 h and analyzed by MTT assay. T. crispa extract
at a concentration of 100.0 mg/mL signiﬁcantly reduced cell
viability to about 50% in HN22 cells and 60% in HSC-3 cells,
while the lower concentrations had no signiﬁcant effect on cell
viability (Figure 2A). By phase contrast microscope, the
morphology of HN22 cells incubated with 50.0 mg/mL of
T. crispa extract was not seen to change compared to the control
(Figure 2B).
3.3. Inhibitory effect of T. crispa extract on MMP-13
expression and protein released
The non-toxic concentrations (12.5, 25.0 and 50.0 mg/mL)
of T. crispa extract were added to HN22 and HSC-3 cells and
after 24-h-culture, the level of MMP-13, TIMP-1 and TIMP-2
mRNA expression was analyzed. T. crispa extract signiﬁcantly
decreased MMP-13 gene expression in a dose-dependent
manner in both cell lines (Figure 3). The expression of
TIMP-1 and TIMP-2 by HN22 cells was not changed in the
presence of T. crispa extract, but T. crispa extract at the dose
of 25.0 and 50.0 mg/mL attenuated the TIMP-2 expression by
HSC-3 cells.
The analysis by ELISA showed that the release of MMP-13
in both cell lines was inhibited after treatment with T. crispa
extract. However, the inhibitory effect of T. crispa extract was
stronger for the HN22 than for the HSC-3 (Figure 4).
3.4. Migration of HN22 cell inhibited by T. crispa
extract
The inﬂuence of T. crispa extract on the migratory po-
tential of HNSCC cells was determined by using the scratch-
wound healing assay. After 24-h-culture, non-treated HN22
cell almost completely ﬁlled up the space created between
cells, but T. crispa extract signiﬁcantly inhibited the cell
migration to 65% compared to the control as shown in
Figure 5.Figure 2. Cytotoxicity of T. crispa extract measured by MTT assay.
A: HN22 and HSC-3 cell viability using MTT assay after treated with
T. crispa extract at concentrations of 12.5, 25.0, 50.0 and 100.0 mg/mL or
DMSO (control) for 48 h; B: The cell morphology observed by phase
contrast microscope; *: Signiﬁcant difference (P < 0.05) compared to
control group.
Figure 4. Inhibition of secreted MMP-13 by T. crispa extract.
Release of MMP-13 in HN22 and HSC-3, treated with various concentra-
tions of T. crispa extract, was analyzed by ELISA; The data was repre-
sented as a relative amount of secreted MMP-13 compared to control.
*: P < 0.05.
Figure 5. Effect of T. crispa on migration of HN22 cells.
A: Photographs of the wound in HN22 cells treated with DMSO (control) or
50 mg/mL extract at time 0 h and 24 h; B: Quantitation of the relative
migration ratio between 0 h and 24 h; *: P < 0.05.
Figure 3. Effect of T. crispa extract on MMP-13 gene expression.
RT-PCR analysis of HSC-3 (A) and HN22 (B) treated with T. crispa extract at different concentrations for 24 h; MMP-13 expression in HSC-3 (C) and
HN22 (D) were normalized to GAPDH; The results represent the mean ± SD relative to the control from three independent experiments; *: P < 0.05.
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The data presented in this study demonstrate that an extract
obtained from T. crispa inhibits the expression of MMP-13 by
HNSCC cell lines. This inhibitory effect was found both at the
gene and at the protein level. Moreover, the extract also
inhibited migration of these cells. Finally, the results conﬁrmed a
higher expression of MMP-13 by metastatic cell lines compared
to the primary cell line. The latter ﬁnding is consistent with
studies which showed that MMP-13 expression was signiﬁcantly
increased in tumors from lymph node metastases in head and
neck squamous cell carcinomas and papillary thyroid carci-
nomas patients [11,24].
It has been shown that MMP-13 plays a role not only in
matrix degradation but also in the activation of other MMPs and
the enzyme appears to be critical in bone metabolism, tumor
invasion and metastasis [5]. We hypothesize that the inhibitory
effect of T. crispa on HNSCC cell migration might be related
to the aberration of MMP-13 expression. Numerous ﬁndings
presented in the literature demonstrated a role for MMP-13 in
cell migration. MMP-13 silencing was shown to decrease tumor
cell migration, whereas over-expression of MMP-13 increased
cell migration and promoted metastasis [8,24]. Whether such a
role of MMP-13 also counts for the cell types we have used,
needs additional experiments.
The anti-proliferation, anti-angiogenic and apoptosis-
inducing effect of T. crispa, were well-documented [21,25], but
the effect on cell migration and MMP-13 suppression have not
been reported before. There is one study demonstrating that
octacosanol isolated from Tinospora cordifolia, another member
of the Menispermaceae family, decreased gelatinolytic activity
of both MMP-2 and MMP-9 in Ehrlich ascites tumor cells [26].
However, MMP-2 and MMP-9 expression was not altered by
T. crispa in our cell lines (data not shown). Interestingly, the
T. crispa-induced inhibition of MMP-13 release by HSC-3 cells
proved to be less effective compared to its effect on HN22 cells.
Similarly, the extract induced a decreased TIMP-2 expression by
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considerable differences between cell lines in their response to
the extract of T. crispa. The mechanisms underlying the dif-
ference in response are not yet known.
A series of chemical constituents such as terpenoids, alka-
loids, ﬂavones and phenolics have been isolated from T. crispa
extracts. Some of these compounds were shown to exert bio-
logical activities. Terpenoids and alkaloids are major active in-
gredients and chemically investigated widely. The terpenoid
glycosides are mainly composed of borapetosides A, B, C, D, E,
F and H [25,27]. Hypoglycemic action of borapetoside has been
shown. Borapetoside A, exerts a glucose-lowering effect,
mainly through an enhanced glucose utilization by peripheral
tissues. This effect was found in both streptozotocin-induced
type 1 diabetes mellitus and diet-induced type 2 diabetes mel-
litus [18]. Alkaloids are well recognized as anti-cancer agents due
to their anti-proliferative and apoptosis-inducing properties
[25,28]. However, the active ingredients responsible for MMP-13
regulation as well as cell migration are still unknown and remain
to be investigated.
In conclusion, T. crispa may exhibit anti-cancer properties
through its ability to modulate MMP-13 expression and to
inhibit cell migration by HNSCC. These data emphasize the
importance of further development of phytochemical agent from
medicinal herb as novel cancer therapeutic drugs.
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